Esketamine nasal spray approved in EU for rapid reduction of depressive symptoms in a psychiatric emergency

This licence extension is specifically for the rapid reduction of depressive symptoms in a psychiatric emergency, for adult patients with a moderate-to-severe episode of major depressive disorder. Approval was based on data from the Phase III ASPIRE I & II clinical studies.

Source:

PharmaTimes